An open label, one year study assessing the ability of SB4 to maintain low disease activity in patients switching from reference etanercept to SB4
Latest Information Update: 18 Nov 2020
At a glance
- Drugs Etanercept (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- 18 Nov 2020 New trial record
- 01 Nov 2020 Results published in the Journal of Dermatological Treatment